Mar. 25 at 5:27 PM
$VRTX
Stock slid from weekly highs (
$512 →
$448), now testing the
$440-445 demand zone. Volatility spiked after that epic run.
Current:
$448.62
50dma:
$468.86 — that's
$20 above current price
Demand zone:
$440-445 (Bollinger lower band at
$439.14)
Here's what the panic sellers don't get:
This isn't a broken stock. It's a coiled spring.
Povetacicept kidney data just dropped — 52% proteinuria reduction, FDA filing by end of March
Analysts still bullish: Truist
$525, Scotiabank
$558, Cantor
$590
90%+ institutional ownership — whales aren't running, they're accumulating
The Maze Therapeutics (MAZE) kidney data drama caused confusion, but analysts called it "clear overreaction." VRTX's FSGS data (47.6% reduction) still solid.
The setup: Price at 50dma discount, volatility expanding, catalyst imminent.
Plan: Stack bids in the
$440-445 zone. First target: reclaim
$468 (50dma). Second:
$525 (analyst PT). Stop below
$435.
Smart money buys weakness.
